Literature DB >> 21681741

Helicobacter pylori infection and the risks of Barrett's oesophagus: a population-based case-control study.

Aaron P Thrift1, Nirmala Pandeya, Kylie J Smith, Adèle C Green, Nicholas K Hayward, Penelope M Webb, David C Whiteman.   

Abstract

Infection with Helicobacter pylori is associated with significantly reduced risks of oesophageal adenocarcinoma; however, few studies have examined the association between H. pylori and Barrett's oesophagus (BO), the precursor lesion. We explored the relationship between H. pylori infection and BO and sought to identify potential modifiers. We compared the prevalence of positive H. pylori serology among 217 adults with simple BO (without dysplasia), 95 with dysplastic BO and 398 population controls sourced from the metropolitan Brisbane area. We determined H. pylori serostatus using enzyme-linked immunosorbent assay. To estimate relative risks, we calculated odds ratios (OR) and 95% confidence intervals (CI) using multivariable logistic regression in the entire sample and stratified by factors known to cause BO. The prevalence of H. pylori seropositivity was 12%, 3%, and 18%, respectively, among patients with simple BO, dysplastic BO and population controls. BO patients were significantly less likely to have antibodies for H. pylori (Simple BO: OR = 0.51, 95% CI: 0.30-0.86; Dysplastic BO: OR = 0.10, 95% CI: 0.03-0.33) than population controls. For simple BO, the association was diminished after adjustment for frequency of gastro-oesophageal reflux (GOR) symptoms. Adjustment for frequency of GOR symptoms did not substantially alter the observed effect for dysplastic BO. Although there was some variation in the magnitude of risk estimates across strata of age, sex, GOR symptoms and use of proton pump inhibitors or H2-receptor antagonists, the differences were uniformly nonsignificant. Helicobacter pylori infection is inversely associated with BO, and our findings suggest that decreased acid load is not the only mechanism underlying the H. pylori protective effect.
Copyright © 2011 UICC.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21681741      PMCID: PMC3306509          DOI: 10.1002/ijc.26242

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  48 in total

1.  Updated guidelines for the diagnosis, surveillance, and therapy of Barrett's esophagus.

Authors:  Richard E Sampliner
Journal:  Am J Gastroenterol       Date:  2002-08       Impact factor: 10.864

Review 2.  Review article: natural history and epidemiology of Helicobacter pylori infection.

Authors:  M F Go
Journal:  Aliment Pharmacol Ther       Date:  2002-03       Impact factor: 8.171

3.  Helicobacter pylori infection is associated with a decreased risk of developing oesophageal neoplasms.

Authors:  J Henrik Simán; A Forsgren; G Berglund; C H Florén
Journal:  Helicobacter       Date:  2001-12       Impact factor: 5.753

4.  Interleukin-1 polymorphisms associated with increased risk of gastric cancer.

Authors:  E M El-Omar; M Carrington; W H Chow; K E McColl; J H Bream; H A Young; J Herrera; J Lissowska; C C Yuan; N Rothman; G Lanyon; M Martin; J F Fraumeni; C S Rabkin
Journal:  Nature       Date:  2000-03-23       Impact factor: 49.962

Review 5.  Barrett's esophagus.

Authors:  Gary W Falk
Journal:  Gastroenterology       Date:  2002-05       Impact factor: 22.682

6.  Eradication of Helicobacter pylori infection induces an increase in body mass index.

Authors:  T Azuma; H Suto; Y Ito; A Muramatsu; M Ohtani; M Dojo; Y Yamazaki; M Kuriyama; T Kato
Journal:  Aliment Pharmacol Ther       Date:  2002-04       Impact factor: 8.171

Review 7.  Helicobacter pylori gastritis and gastric physiology.

Authors:  K E McColl; E el-Omar; D Gillen
Journal:  Gastroenterol Clin North Am       Date:  2000-09       Impact factor: 3.806

8.  Prevalence of Barrett's esophagus in asymptomatic individuals.

Authors:  Lauren B Gerson; Katerina Shetler; George Triadafilopoulos
Journal:  Gastroenterology       Date:  2002-08       Impact factor: 22.682

9.  Helicobacter pylori induces apoptosis in Barrett's-derived esophageal adenocarcinoma cells.

Authors:  Andrew D Jones; Kathy D Bacon; Blair A Jobe; Brett C Sheppard; Clifford W Deveney; Michael J Rutten
Journal:  J Gastrointest Surg       Date:  2003-01       Impact factor: 3.452

10.  Atrophic gastritis and Helicobacter pylori infection in outpatients referred for gastroscopy.

Authors:  A Oksanen; P Sipponen; R Karttunen; A Miettinen; L Veijola; S Sarna; H Rautelin
Journal:  Gut       Date:  2000-04       Impact factor: 23.059

View more
  24 in total

1.  Risk factors associated with Barrett's epithelial dysplasia.

Authors:  Mikiko Fujita; Yuri Nakamura; Saeko Kasashima; Maiko Furukawa; Ryoichi Misaka; Hikaru Nagahara
Journal:  World J Gastroenterol       Date:  2014-04-21       Impact factor: 5.742

2.  Carcinogenesis of Barrett's esophagus: a review of the clinical literature.

Authors:  Jiro Watari; Tadayuki Oshima; Hirokazu Fukui; Toshihiko Tomita; Hiroto Miwa
Journal:  Clin J Gastroenterol       Date:  2013-08-14

3.  Gastric Helicobacter pylori Infection Affects Local and Distant Microbial Populations and Host Responses.

Authors:  Sabine Kienesberger; Laura M Cox; Alexandra Livanos; Xue-Song Zhang; Jennifer Chung; Guillermo I Perez-Perez; Gregor Gorkiewicz; Ellen L Zechner; Martin J Blaser
Journal:  Cell Rep       Date:  2016-02-04       Impact factor: 9.423

Review 4.  Population screening and treatment of Helicobacter pylori infection.

Authors:  Anthony O'Connor; Colm A O'Morain; Alexander C Ford
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2017-01-05       Impact factor: 46.802

5.  The frequency of histologically confirmed Barrett's esophagus varies by the combination of ethnicity and gender.

Authors:  Sian S Chisholm; Joe E Khoury; M Mazen Jamal; Carlos Palacio; Sunitha Pudhota; Kenneth J Vega
Journal:  J Gastrointest Oncol       Date:  2017-02

6.  Aspirin and nonsteroidal anti-inflammatory drug use and the risk of Barrett's esophagus.

Authors:  Jennifer L Schneider; Wei K Zhao; Douglas A Corley
Journal:  Dig Dis Sci       Date:  2014-09-12       Impact factor: 3.199

7.  Primary esophageal adenocarcinoma with distant metastasis to the skeletal muscle.

Authors:  Makoto Sohda; Hitoshi Ojima; Akihiko Sano; Yasuyuki Fukai; Hiroyuki Kuwano
Journal:  Int Surg       Date:  2014 Sep-Oct

8.  Risk of esophageal adenocarcinoma decreases with height, based on consortium analysis and confirmed by Mendelian randomization.

Authors:  Aaron P Thrift; Harvey A Risch; Lynn Onstad; Nicholas J Shaheen; Alan G Casson; Leslie Bernstein; Douglas A Corley; David M Levine; Wong-Ho Chow; Brian J Reid; Yvonne Romero; Laura J Hardie; Geoffrey Liu; Anna H Wu; Nigel C Bird; Marilie D Gammon; Weimin Ye; David C Whiteman; Thomas L Vaughan
Journal:  Clin Gastroenterol Hepatol       Date:  2014-02-12       Impact factor: 11.382

9.  Exploring the recent trend in esophageal adenocarcinoma incidence and mortality using comparative simulation modeling.

Authors:  Chung Yin Kong; Sonja Kroep; Kit Curtius; William D Hazelton; Jihyoun Jeon; Rafael Meza; Curtis R Heberle; Melecia C Miller; Sung Eun Choi; Iris Lansdorp-Vogelaar; Marjolein van Ballegooijen; Eric J Feuer; John M Inadomi; Chin Hur; E Georg Luebeck
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2014-04-01       Impact factor: 4.254

10.  Risk of histologic Barrett's esophagus between African Americans and non-Hispanic whites: A meta-analysis.

Authors:  Ahmad Alkaddour; Carlos Palacio; Kenneth J Vega
Journal:  United European Gastroenterol J       Date:  2017-05-07       Impact factor: 4.623

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.